ARCHIVES

NCI Planning To Switch Drug Development Emphasis From Compound To Human Cancer Oriented Strategy

This article is from The Cancer Letter archive.

Vol. 10 No. 41 | October 26, 1984

Download PDF Visit The Full Archive

Related Articles

ACS Says 41 Percent Survive 5 Years

January 2, 1981

ACCC Asks More Community Representation, Clear Separation From Centers In New NCI Division

June 29, 1979

Fox Chase, UCLA, U. Washington Win Neutron Contracts

October 5, 1979

Sanofi: Zaltrap Price Reflects Competing Drugs In Second-Line Metastatic Colon Cancer

November 1, 2012

FDA Seeks Consumers For Advisory Committees.

November 23, 2001

NCCS Networker Volume 1 Issue 2, Summer 1987

June 13, 1987